You can buy or sell Lipocine and other stocks, options, ETFs, and crypto commission-free!
Lipocine, Inc. operates as a pharmaceutical company, which engages in the research and development of treatment for use in men's and women's health through proprietary drug delivery technologies. It focuses on the oral testosterone replacement therapy and preterm birth prevention. Read More The company was founded in 2011 and is headquartered in Salt Lake City, UT.
Salt Lake City, Utah
52 Week High
52 Week Low
Research And Development
PR NewswireMar 21
Lipocine to Participate at the ROTH Battle of the NASH Thrones Spring Investor Conference
SALT LAKE CITY, March 21, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview and LPCN 1144's therapeutic potential for non-alcoholic steatohepatitis ("NASH") at the ROTH Battle of the NASH Thrones Spring Investor Conference, being held March 28, 2019 in New York City. ROTH Battle of the NASH Thrones Spring Investor Conference Date: Thursday, March 28th Location: Park Hya...
PR NewswireMar 14
Lipocine Announces Presentation Highlighting Therapeutic Potential of LPCN 1144 in NAFLD and NASH Selected for ENDO 2019
SALT LAKE CITY, March 14, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 clinical results as part of ENDO 2019. The presentation will highlight the therapeutic potential of LPCN 1144 in non-alcoholic fatty liver disease ("NAFLD") and non-alcoholic steatohepatitis ("NASH"). ENDO 2019 is being held March 23rd – 26th in New Orleans, LA. Presentation Details Title: Therapeutic Potential of LPCN 1144 in NAFLD...
Expected May 6, Pre-Market